ABMC Reports First Quarter 2015 Results

KINDERHOOK, N.Y.--(BUSINESS WIRE)--

American Bio Medica Corporation ABMC today announced financial results for the three months ended March 31, 2015.

Chief Executive Officer Melissa A. Waterhouse stated, "The decline in sales in the first quarter 2015 was primarily due to the loss of two state contracts in 2014 (both of which are now using a product manufactured outside of the United States). In addition, contract-manufacturing sales declined as a result of an inventory surplus at one of our contract-manufacturing customers. The surplus has been used and we expect contract-manufacturing levels to return to a level more in line with historical sales."

Waterhouse continued, "A couple months ago, I indicated that 2015 was expected to be a year of investment in selling and marketing and our recent sales levels demonstrate the need for such an investment. In the first quarter of 2015, we hired additional sales representatives to target our core markets in the United States, increased our market presence at industry trade shows, and began new marketing initiatives. Our application for OTC marketing clearance of our urine-based all-inclusive drug test is still under FDA review but we are hopeful that we will have FDA's decision on the application in the very near future. New assay development continues and is going well."

Financial Highlights

• Net sales in the first quarter of 2015 were $1,502,000 compared to $2,043,000 in the first quarter of 2014, a decrease of 26.5%.
• Operating loss was $53,000 in the first quarter of 2015 compared to an operating profit of $62,000 in first quarter of 2014.
• Net loss was $45,000 in the first quarter 2015 compared to net income of 9,000 in the first quarter 2014.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, including but not limited to our ability to obtain marketing clearance on our OralStat product, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to "penny stock" rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-K for the year ended December 31, 2014, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

AMERICAN BIO MEDICA CORPORATION
Condensed Statements of Operations
(unaudited)
			For the three				For the three
			months ended				months ended
			March 31, 2014				March 31, 2014
Net sales		$	1,502,000			$	2,043,000
Cost of goods sold			802,000				1,166,000
Gross profit			700,000				877,000
Operating expenses:
Research and development			29,000				46,000
Selling and marketing			299,000				292,000
General and administrative			425,000				477,000
Total operating expenses			753,000				815,000
Operating income / (loss)			(53,000	)			62,000
Other income/ (expense)			8,000				(52,000	)
Net income / (loss) before tax			(45,000	)			10,000
Income tax expense			0				(1,000	)
Net income / (loss)		$	(45,000	)		$	9,000
Basic & diluted income / (loss) per common share		$	(0.00	)		$	0.00
Weighted average shares outstanding – basic			24,589,340				23,168,155
Weighted average shares outstanding – diluted			24,589,340				23,260,582

American Bio Medica Corporation
Condensed Balance Sheets
			March 31,				December 31,
			2015				2015
			(unaudited)
ASSETS
Current Assets
Cash and cash equivalents		$	487,000			$	352,000
Accounts receivable, net of allowance for doubtful accounts of $45,000 at March 31, 2015 and $47,000 at December 31, 2014			648,000				814,000
Inventory, net of allowance of $345,000 at March 31, 2015 and $324,000 at December 31, 2014			1,812,000				1,722,000
Current portion of deferred financing			57,000				43,000
Prepaid expenses and other current assets			103,000				85,000
Total current assets			3,107,000				3,016,000
Property, plant and equipment, net			957,000				983,000
Patents, net			67,000				65,000
Other assets			14,000				14,000
Deferred finance costs			106,000				0
Total assets		$	4,251,000			$	4,078,000
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable			423,000				410,000
Accrued expenses and other current liabilities			175,000				192,000
Wages payable			302,000				264,000
Line of credit, net			945,000				979,000
Current portion of long-term debt, net			32,000				858,000
Total current liabilities			1,877,000				2,703,000
Other liabilities			68,000				68,000
Related party note			124,000				124,000
Long-term debt			956,000				213,000
Total liabilities			3,025,000				3,108,000
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity:
Common stock			260,000				236,000
Additional paid-in capital			20,633,000				20,356,000
Accumulated deficit			(19,667,000	)			(19,622,000	)
Total stockholders' equity			1,226,000				970,000
Total liabilities and stockholders' equity		$	4,251,000			$	4,078,000